000 02289 a2200637 4500
005 20250518045401.0
264 0 _c20191030
008 201910s 0 0 eng d
022 _a2352-3026
024 7 _a10.1016/S2352-3026(19)30088-2
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSandmaier, Brenda M
245 0 0 _aAddition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
_h[electronic resource]
260 _bThe Lancet. Haematology
_cAug 2019
300 _ae409-e418 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study
650 0 4 _aAged
650 0 4 _aCyclosporine
_xtherapeutic use
650 0 4 _aDisease-Free Survival
650 0 4 _aDrug Therapy, Combination
650 0 4 _aFemale
650 0 4 _aGraft vs Host Disease
_xmortality
650 0 4 _aHLA Antigens
_xmetabolism
650 0 4 _aHematopoietic Stem Cell Transplantation
_xadverse effects
650 0 4 _aHumans
650 0 4 _aImmunosuppressive Agents
_xtherapeutic use
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aMycophenolic Acid
_xtherapeutic use
650 0 4 _aProportional Hazards Models
650 0 4 _aRecurrence
650 0 4 _aSirolimus
_xtherapeutic use
650 0 4 _aSurvival Rate
650 0 4 _aTransplantation, Homologous
650 0 4 _aTreatment Outcome
650 0 4 _aWhole-Body Irradiation
700 1 _aKornblit, Brian
700 1 _aStorer, Barry E
700 1 _aOlesen, Gitte
700 1 _aMaris, Michael B
700 1 _aLangston, Amelia A
700 1 _aGutman, Jonathan A
700 1 _aPetersen, Soeren L
700 1 _aChauncey, Thomas R
700 1 _aBethge, Wolfgang A
700 1 _aPulsipher, Michael A
700 1 _aWoolfrey, Ann E
700 1 _aMielcarek, Marco
700 1 _aMartin, Paul J
700 1 _aAppelbaum, Fred R
700 1 _aFlowers, Mary E D
700 1 _aMaloney, David G
700 1 _aStorb, Rainer
773 0 _tThe Lancet. Haematology
_gvol. 6
_gno. 8
_gp. e409-e418
856 4 0 _uhttps://doi.org/10.1016/S2352-3026(19)30088-2
_zAvailable from publisher's website
999 _c29845407
_d29845407